Advances in Parkinson's Disease最新文献_第2页

Problems Associated with Non-Ergot Dopamine Agonist Maintenance Therapy in Patients with Advanced Parkinson’s Disease 晚期帕金森病患者非麦角多巴胺激动剂维持治疗相关问题

Advances in Parkinson's Disease Pub Date : 2019-08-26 DOI: 10.4236/apd.2019.83004

M. Shiraishi, F. Maki, N. Sasaki, Y. Hasegawa

引用次数: 0

Clinical Experience with Generic Rasagiline (Ralago®) in Patients with Parkinson’s Disease: An Open-Label, Multicenter, Observational Study 雷沙吉兰(Ralago®)治疗帕金森病患者的临床经验:一项开放标签、多中心、观察性研究

Advances in Parkinson's Disease Pub Date : 2019-05-27 DOI: 10.4236/APD.2019.82003

D. Pintér, J. Lajtos, J. Janszky, N. Kovács

{"title":"Clinical Experience with Generic Rasagiline (Ralago®) in Patients with Parkinson’s Disease: An Open-Label, Multicenter, Observational Study","authors":"D. Pintér, J. Lajtos, J. Janszky, N. Kovács","doi":"10.4236/APD.2019.82003","DOIUrl":"https://doi.org/10.4236/APD.2019.82003","url":null,"abstract":"Background: Antiparkinsonian pharmacotherapy represents one of the most important expenses related to Parkinson’s disease. The application of generic drugs may help to reduce the economic burden of the disease; however, efficacy and safety of these products have been less studied. Objective: To investigate the efficacy and safety of generic rasagiline (Ralago®) from a clinical perspective. Methods: The Clinical Global Impression of Severity scale was used to rate the most important motor and non-motor symptoms at baseline and 12 weeks after the initiation of Ralago®. Patients also identified symptoms which were the main sources of their disability and distress in everyday life. Results: A total of 499 patients were enrolled (231 females, mean age: 73.2 ± 9.1 years, mean duration of disease: 3.6 ± 3.7 years). Of them, 486 patients completed the study protocol. Both motor and non-motor symptoms showed improvement during 12-week Ralago® treatment. Adverse events were rare, and the majority of them were not considered as serious. Conclusions: The generic rasagiline (Ralago®) is an effective and safe generic product.","PeriodicalId":7350,"journal":{"name":"Advances in Parkinson's Disease","volume":"88 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76052714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

A Report of 10 Cases of Parkinson’s Disease Cured by Xifengzhizhan Pills and Xifengzhizhan Capsules 喜风止战丸与喜风止战胶囊治疗帕金森病10例报告

Advances in Parkinson's Disease Pub Date : 2019-05-20 DOI: 10.4236/APD.2019.82002

Weifan Wang

引用次数: 0

Usefulness of Enteral Nutritional Intake Containing Median-Chain Fatty Acids in Parkinson’s Disease Patients with Weight Loss: A Pilot Study 含中链脂肪酸的肠内营养摄入对帕金森病患者体重减轻的有效性:一项初步研究

Advances in Parkinson's Disease Pub Date : 2019-02-28 DOI: 10.4236/apd.2019.81001

M. Shiraishi, K. Isahaya, Y. Hasegawa

{"title":"Usefulness of Enteral Nutritional Intake Containing Median-Chain Fatty Acids in Parkinson’s Disease Patients with Weight Loss: A Pilot Study","authors":"M. Shiraishi, K. Isahaya, Y. Hasegawa","doi":"10.4236/apd.2019.81001","DOIUrl":"https://doi.org/10.4236/apd.2019.81001","url":null,"abstract":"Background: No solution has yet been found for the nutritional issues of Parkinson’s disease (PD) patients with weight loss, which affects their prognosis. The objective of the present study was to investigate whether a defined-formula diet rich in ω3 fatty acids improved nutrition through the effect of ghrelin in PD patients with weight loss. Method: Weight, serum total protein, albumin, lipids, serum ghrelin, serum acylghrelin, leptin, and the Unified Parkinson’s Disease Rating Scale were monitored for approximately 3 months in 11 subjects given a defined-formula diet rich in ω3 fatty acids for 3 months and 5 control subjects who received no such treatment. Results: No significant changes from baseline in serum ghrelin, acylghrelin, and leptin levels were noted after administration of the nutritional product. Meanwhile, compared with the control, changes from baseline in the levels of albumin and weight were significant after the nutritional therapy rich in ω3 fatty acids (P < 0.05). Conclusion: Administration of a medium-chain fatty acid-rich product has few effects on motor functions and activities of daily living in PD patients with weight loss, but it is expected to offer effective ghrelin-mediated nutritional improvement.","PeriodicalId":7350,"journal":{"name":"Advances in Parkinson's Disease","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85352498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0